Share
Dr. Volker Knappertz
Noema Pharma, a clinical-stage biotech company dedicated to advancing treatments for debilitating central nervous system (CNS) disorders, announced the appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development.
With over 25 years of experience in drug development, Dr. Knappertz has played a pivotal role in numerous IND filings and product approvals. Prior to joining Noema, he served as EVP of R&D at Aurinia Pharmaceuticals, leading multiple programs in autoimmune diseases. Previously, he was EVP of R&D and Chief Medical Officer at GW Pharmaceuticals, where he was instrumental in securing FDA approval for Epidiolex, a breakthrough treatment for rare pediatric epilepsy.
Dr. Knappertz has also held leadership positions at Teva Pharmaceuticals, AstraZeneca, and Bayer, contributing to major drug approvals and business development deals. A US board-certified neurologist, he earned his medical degree from Cologne University and has served as an Adjunct Professor in Neurology at the University of Pennsylvania and Heinrich-Heine University in Düsseldorf.
His extensive expertise will be invaluable as Noema Pharma advances its pipeline of transformative CNS therapies.
